154 related articles for article (PubMed ID: 7686766)
1. Treatment of carcinoid syndrome with recombinant interferon alpha-2a.
Di Bartolomeo M; Bajetta E; Zilembo N; de Braud F; Di Leo A; Verusio C; D'Aprile M; Scanni A; Barduagni M; Barduagni A [corrected to Barduagni M]
Acta Oncol; 1993; 32(2):235-8. PubMed ID: 7686766
[TBL] [Abstract][Full Text] [Related]
2. Recombinant alpha-2b interferon in patients with malignant carcinoid tumour.
Basser RL; Lieschke GJ; Sheridan WP; Fox RM; Green MD
Aust N Z J Med; 1991 Dec; 21(6):875-8. PubMed ID: 1726359
[TBL] [Abstract][Full Text] [Related]
3. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
Janson ET; Oberg K
Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group.
Bajetta E; Zilembo N; Di Bartolomeo M; Di Leo A; Pilotti S; Bochicchio AM; Castellani R; Buzzoni R; Celio L; Dogliotti L
Cancer; 1993 Nov; 72(10):3099-105. PubMed ID: 7693327
[TBL] [Abstract][Full Text] [Related]
5. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
Rubin J; Ajani J; Schirmer W; Venook AP; Bukowski R; Pommier R; Saltz L; Dandona P; Anthony L
J Clin Oncol; 1999 Feb; 17(2):600-6. PubMed ID: 10080605
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of metastasized carcinoid tumor of the ileum and cecum with recombinant alpha-2b interferon].
Doberauer C; Niederle N; Kloke O; Kurschel E; Schmidt CG
Onkologie; 1987 Dec; 10(6):340-4. PubMed ID: 2450326
[TBL] [Abstract][Full Text] [Related]
7. Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested?
Välimäki M; Järvinen H; Salmela P; Sane T; Sjöblom SM; Pelkonen R
Cancer; 1991 Feb; 67(3):547-9. PubMed ID: 1702352
[TBL] [Abstract][Full Text] [Related]
8. Treatment of metastatic carcinoid tumour with recombinant interferon alfa.
Joensuu H; Kumpulainen E; Gröhn P
Eur J Cancer; 1992; 28A(10):1650-3. PubMed ID: 1382493
[TBL] [Abstract][Full Text] [Related]
9. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
[TBL] [Abstract][Full Text] [Related]
10. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.
Biesma B; Willemse PH; Mulder NH; Verschueren RC; Kema IP; de Bruijn HW; Postmus PE; Sleijfer DT; de Vries EG
Br J Cancer; 1992 Nov; 66(5):850-5. PubMed ID: 1384643
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study.
Jacobsen MB; Hanssen LE; Kolmannskog F; Schrumpf E; Vatn MH; Bergan A
Scand J Gastroenterol; 1995 Aug; 30(8):789-96. PubMed ID: 7481548
[TBL] [Abstract][Full Text] [Related]
12. A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour.
Veenhof CH; de Wit R; Taal BG; Dirix LY; Wagstaff J; Hensen A; Huldij AC; Bakker PJ
Eur J Cancer; 1992; 28(1):75-8. PubMed ID: 1373635
[TBL] [Abstract][Full Text] [Related]
13. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon.
Moertel CG; Rubin J; Kvols LK
J Clin Oncol; 1989 Jul; 7(7):865-8. PubMed ID: 2738623
[TBL] [Abstract][Full Text] [Related]
14. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity.
Oberg K; Alm G; Magnusson A; Lundqvist G; Theodorsson E; Wide L; Wilander E
J Natl Cancer Inst; 1989 Apr; 81(7):531-5. PubMed ID: 2466128
[TBL] [Abstract][Full Text] [Related]
15. Combined alpha- and gamma-interferon therapy for malignant midgut carcinoid tumors. A phase I-II trial.
Janson ET; Kauppinen HL; Oberg K
Acta Oncol; 1993; 32(2):231-3. PubMed ID: 8323762
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of metastatic carcinoid tumors with interferon-alpha. Five cases].
Votte A; Iglicki F; Sévenet F; Tabah I; Dupas JL
Presse Med; 1996 Jan; 25(2):63-7. PubMed ID: 8745720
[TBL] [Abstract][Full Text] [Related]
17. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
Ruszniewski P; Ish-Shalom S; Wymenga M; O'Toole D; Arnold R; Tomassetti P; Bax N; Caplin M; Eriksson B; Glaser B; Ducreux M; Lombard-Bohas C; de Herder WW; Delle Fave G; Reed N; Seitz JF; Van Cutsem E; Grossman A; Rougier P; Schmidt W; Wiedenmann B
Neuroendocrinology; 2004; 80(4):244-51. PubMed ID: 15627802
[TBL] [Abstract][Full Text] [Related]
18. [Therapy of metastatic carcinoid with the somatostatin analog octreotide and with recombinant interferon alfa 2b].
Linkesch M; Kuzmits R; Geyer G
Wien Klin Wochenschr; 1989 Jun; 101(13):455-7. PubMed ID: 2763566
[TBL] [Abstract][Full Text] [Related]
19. Efficient symptomatic control of carcinoid tumors with somatostatin in patients with disease progression under alpha-interferon therapy.
Boehme MW; Schmidt-Gayk H; Bihl H; Eisenhut M; Herfarth CH; Kommere B; Raeth U
Hepatogastroenterology; 1995; 42(6):1053-61. PubMed ID: 8847018
[TBL] [Abstract][Full Text] [Related]
20. Treatment of metastatic carcinoid tumors and the carcinoid syndrome with recombinant interferon alpha.
Doberauer C; Mengelkoch B; Kloke O; Wandl U; Niederle N
Acta Oncol; 1991; 30(5):603-5. PubMed ID: 1892678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]